Next Article in Journal
Oxidative Stress: Role and Response of Short Guanine Tracts at Genomic Locations
Next Article in Special Issue
Omega-3 Fatty Acid-Derived Resolvin D2 Regulates Human Placental Vascular Smooth Muscle and Extravillous Trophoblast Activities
Previous Article in Journal
Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas
Previous Article in Special Issue
Omega-3 Docosahexaenoic Acid Is a Mediator of Fate-Decision of Adult Neural Stem Cells
Open AccessReview

Omega-3 Fatty Acids and Neurodegenerative Diseases: New Evidence in Clinical Trials

1
Department of Life Sciences, Modena and Reggio Emilia University, 41125 Modena, Italy
2
Division of Geriatric Medicine, Department of Biomedical, Metabolic and Neural Sciences, and Center for Gerontological Evaluation and Research, Modena and Reggio Emilia University, 41126 Modena, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(17), 4256; https://doi.org/10.3390/ijms20174256
Received: 24 July 2019 / Revised: 26 August 2019 / Accepted: 28 August 2019 / Published: 30 August 2019
(This article belongs to the Special Issue Omega-3 Fatty Acids in Health and Disease: New Knowledge 2019)
A nutritional approach could be a promising strategy to prevent or slow the progression of neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease, since there is no effective therapy for these diseases so far. The beneficial effects of omega-3 fatty acids are now well established by a plethora of studies through their involvement in multiple biochemical functions, including synthesis of anti-inflammatory mediators, cell membrane fluidity, intracellular signaling, and gene expression. This systematic review will consider epidemiological studies and clinical trials that assessed the impact of supplementation or dietary intake of omega-3 polyunsaturated fatty acids on neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases. Indeed, treatment with omega-3 fatty acids, being safe and well tolerated, represents a valuable and biologically plausible tool in the management of neurodegenerative diseases in their early stages. View Full-Text
Keywords: omega-3 polyunsaturated fatty acids; Parkinson’s disease; Alzheimer’s disease; clinical trials omega-3 polyunsaturated fatty acids; Parkinson’s disease; Alzheimer’s disease; clinical trials
Show Figures

Figure 1

MDPI and ACS Style

Avallone, R.; Vitale, G.; Bertolotti, M. Omega-3 Fatty Acids and Neurodegenerative Diseases: New Evidence in Clinical Trials. Int. J. Mol. Sci. 2019, 20, 4256.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop